# Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

> **NCT05715918** · PHASE3 · UNKNOWN · sponsor: **Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products** · enrollment: 300 (estimated)

## Conditions studied

- Vaccine

## Interventions

- **BIOLOGICAL:** Vaccine for intramuscular injection
- **OTHER:** Placebo comparator (without active ingredient) for intramuscular injection

## Key facts

- **NCT ID:** NCT05715918
- **Lead sponsor:** Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715918, "Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05715918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*